GeneBiology
Private Company
Funding information not available
Overview
GeneBiology is a private, development-stage biotech company utilizing the efficient 505(b)(2) regulatory pathway to develop patented new formulations of existing drugs. Its strategy centers on reducing development time, cost, and risk by relying on prior safety and efficacy data. The company has two disclosed programs in its pipeline for vertigo/motion sickness and tamoxifen-resistant breast cancer, and it operates with private funding, intending to remain private. Its long-term vision is modeled on successful private pharmaceutical firms like the former Burroughs Wellcome Co.
Technology Platform
Expertise in leveraging the FDA's 505(b)(2) regulatory pathway to develop new formulations, new routes of administration, and new indications for previously approved drugs, minimizing development time and risk.
Opportunities
Risk Factors
Competitive Landscape
GeneBiology competes with other specialty pharma companies utilizing the 505(b)(2) strategy, as well as generic manufacturers and originator companies defending their branded products. In breast cancer, it faces intense competition from novel targeted therapies and next-generation endocrine agents. In nausea/vertigo, it competes with a range of established generic and OTC products.